Unmet Need
- Many therapies still hit non-tumor targets, causing toxicity and limited efficacy.
- MELTF is overexpressed on multiple cancers and low in healthy tissues, offering a tumor-selective entry point.
Our Innovation
- We develop antibodies that recognize MELTF on cancer cells and are readily internalized after binding.
- By linking these antibodies to a cytotoxic payload (forming an ADC), the drug is carried inside tumor cells and released where it’s needed, aiming to kill cancer cells while sparing normal tissue.
Advantages
- Selectivity: Targeting MELTF aims for a wider therapeutic window than many current targets.
- Designed for delivery: Internalizing antibodies are well-suited to payload delivery (a key ADC requirement).
- Translatable modality: Clear path from research-grade antibodies to developable ADC candidates.
Commercial Opportunity
We are seeking collaboration with oncology biopharma and ADC developers for co-development, licensing, and strategic investment. Ideal partners bring ADC chemistry/CMC, preclinical translation, and early clinical capabilities.
Contact in Yissum: Ariela Markel
